Targets › HIST1H3A
1 program from 1 company in 1 trial: 1 Phase 1; Respiratory; next expected readout Jan 2027.
Open in Phaseline: the race on HIST1H3A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| HTIC | HT31-1 humanized monoclonal antibody against citrullinated histone H3 | HIST1H3A | Phase 1 | ARDS (Acute Respiratory Distress Syndrome) | Jan 2027 |
ARDS (Acute Respiratory Distress Syndrome) (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.